Sentences with phrase «for myelofibrosis»

Background: Available therapies for myelofibrosis can exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia.

«Ruxolitinib for myelofibrosis: Indication of considerable added benefit.»

Currently, the only treatment for myelofibrosis is Incyte's Jakafi, which generated sales and royalty revenue at an annualized run rate of $ 1.01 billion based on third - quarter results.

Not exact matches

The underlying reason is that Geron and partner Johnson & Johnson (NYSE: JNJ) are developing a first - in - class telomerase inhibitor called imetelstat for the rare blood disorders myelodysplastic syndromes (MDS) and myelofibrosis (MF).

Incyte's (NASDAQ: INCY) Jakafi racked up $ 1.1 billion in sales last year as the only targeted therapy for patients with myelofibrosis, but a majority of patients who take it eventually relapse.

In preliminary drug - mutation matching studies, they found that JAK1 - mutated SS cells were sensitive to JAK inhibitors, drugs that are currently approved for treatment of other hematologic cancers such as polycythemia vera and myelofibrosis.

Ruxolitinib (trade name: Jakavi) has been approved since August 2012 for the treatment of adults with myelofibrosis.

Ruxolitinib is an option for patients with so - called primary or secondary myelofibrosis whose spleen is already enlarged (splenomegaly) or who have other disease - related symptoms.

But especially in the case of advanced myelofibrosis and systemic mastocytosis, patients may survive only for several years.

A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.

Patients with higher - risk myelofibrosis (with no exclusions for baseline anaemia or thrombocytopenia) were randomly assigned (2:1) to receive oral pacritinib 400 mg once daily or best available therapy (BAT) excluding JAK2 inhibitors until disease progression or unacceptable toxicity.

Pacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited.